Regulatory dispatch
BPC-157: how it got to PCAC
Background
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a sequence the original investigators isolated from human gastric juice. It has no FDA-approved indication, no approved marketing authorization in any major jurisdiction, and no USP or NF monograph. Its presence in U.S. commerce is therefore tied entirely to the compounding regulations of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
The peptide is now scheduled for review at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026, as one of four peptide-class bulk drug substances FDA is asking the committee to weigh for the 503A Bulks List (FDA — July 23-24, 2026 PCAC meeting).
The original nomination
BPC-157 was nominated to the 503A bulk drug substances list during the original public nomination window FDA opened in 2013–2014 after the Drug Quality and Security Act was enacted. The agency received nominations for hundreds of substances, BPC-157 among them, from compounding pharmacies and trade groups (FDA — Bulk Drug Substances Used in Compounding).
Category 2 placement
After FDA’s preliminary review, BPC-157 was placed in “Category 2” — the bucket for nominated substances that FDA had identified as raising significant safety concerns and that the agency would not cover under enforcement discretion while the bulks list was being developed (FDA — Significant Safety Risks).
The factors FDA cited in its prior interim materials for Category 2 placement included the absence of an FDA-approved drug containing the substance, the lack of a USP or NF monograph, the absence of large-scale human safety data, and questions about the chemical characterization and purity of bulk material being supplied to compounders. Independent academic reviewers have separately observed that the published BPC-157 evidence base is dominated by preclinical (rodent and in-vitro) studies, with only a handful of small human protocols (McGuire et al. 2025).
Limited human data
The clinical record on BPC-157 in humans is limited. The 2025 University of Utah scoping review by McGuire and colleagues reported that only three pilot human studies have been published — covering intraarticular knee pain, interstitial cystitis, and an intravenous safety/pharmacokinetics protocol — and concluded that no rigorous large-scale trials had been completed at the time of writing.
Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.
A registered Phase I oral pharmacokinetics and safety trial (NCT02637284), sponsored by PharmaCotherapia d.o.o. and conducted at Hospital Ángeles Tijuana, was last reported as “active, not recruiting” in 2015, with no results posted to ClinicalTrials.gov as of this writing (NCT02637284).
Removal from Category 2 and route to PCAC
In April 2026, FDA announced that BPC-157 had been removed from Category 2 because the original nominators withdrew the underlying nominations. Removal from Category 2 does not, by itself, place a substance on the 503A Bulks List — it only ends the prior categorization. The agency simultaneously announced that it would take BPC-157, along with KPV, TB-500, and MOTs-C, to the PCAC for a full review at the July 23-24, 2026 meeting (FDA — July 23-24, 2026 PCAC meeting).
According to FDA’s meeting announcement, the use evaluated for BPC-157 (free base) and BPC-157 acetate is ulcerative colitis. That framing reflects the indication around which the most coherent body of preclinical and early-clinical evidence has accumulated, and it narrows the committee’s review to a specific therapeutic context rather than a generic “tissue healing” claim.
What the July 2026 meeting will weigh
The PCAC’s review will follow FDA’s standard four-factor framework: physical and chemical characteristics, safety, evidence of effectiveness, and historical use in compounded drug products. The committee will hear FDA’s briefing presentation, a short presentation from any nominator that elects to speak, and public comments.
The four-factor balance for BPC-157 is open in every category. The peptide is well-characterized chemically (a defined 15-residue sequence with documented analytical methods), but bulk-supply purity and impurity profiles will be a likely focus. Safety data is dominated by rodent toxicology and small-cohort pilot human work. Effectiveness evidence in the proposed indication (ulcerative colitis) is largely preclinical. Historical compounding use in the United States is documented but largely in the post-2013 era and concentrated in non-traditional settings.
What’s at stake
A favorable PCAC vote followed by FDA rulemaking would create the first lawful 503A compounding pathway for BPC-157 in the United States. An unfavorable vote, or no FDA action, leaves BPC-157 outside the regulated compounding pathway entirely — neither monograph-covered nor a component of an FDA-approved drug, and therefore not eligible for 503A compounding by operation of the statute.